English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Epidermal growth factor receptor (EGFR) and lanthionine synthetase C-like 2 (LanCL2) genes locate in the same amplicon, and co-amplification of  EGFR  and  LANCL2  is frequent in glioblastoma. However, the prognostic value of  LANCL2  and  EGFR  co-amplification, and their mRNA and protein expression in glioblastoma remain unclear yet.    Methods  This study analyzed the prognostic values of the copy number variations (CNVs), mRNA and protein expression of  LANCL2  and  EGFR  in 575 glioblastoma patients in TCGA database and 100 glioblastoma patients in tumor banks of the Shenzhen Second People’s Hospital and the Sun Yat-sen University Cancer Center.    Results  The amplification of  LANCL2  or  EGFR , and their co-amplification were frequent in glioblastoma of TCGA database and our tumor banks. A significant correlation was found between the CNVs of  LANCL2  and  EGFR  ( p  < 0.001). CNVs of  LANCL2  or  EGFR  were significantly correlated with  IDH1/2  mutation but not  MGMT  promoter methylation. Multivariate analysis showed that  LANCL2  amplification was significantly correlated with reduced overall survival (OS) in younger (< 60 years) glioblastoma patients of TCGA database ( p  = 0.043, HR = 1.657) and our tumor banks ( p  = 0.018, HR = 2.199). However,  LANCL2  or  EGFR  amplification, and their co-amplification had no significant impact on OS in older (≥ 60 years) or  IDH1/2 -wild-type glioblastoma patients. mRNA and protein overexpression of LANCL2 and EGFR was also frequently found in glioblastoma. The mRNA expression rather than the protein expression of  LANCL2  and  EGFR  was positively correlated ( p  < 0.001). However, mRNA or protein expression of EGFR and LANCL2 was not significantly correlated with OS of glioblastoma patients. The protein expression level of LANCL2, rather than EGFR, was elevated in relapsing glioblastoma, compared with newly diagnosed glioblastoma. In addition, the intracellular localization of LanCL2, not EGFR, was associated with the grade of gliomas.    Conclusions  Taken together, amplification and mRNA overexpression of  LANCL2  and  EGFR , and their co-amplification and co-expression were frequent in glioblastoma patients. Our findings suggest that amplification of  LANCL2  and  EGFR  were the independent diagnostic biomarkers for glioblastoma patients, and  LANCL2  amplification was a significant prognostic factor for OS in younger glioblastoma patients.    Supplementary Information  The online version contains supplementary material available at 10.1186/s12967-021-02979-z.

Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients